GlassScriptPhysician profile
Bruce Robert Stevens
NPI 1003870379
$4,237.56
in general payments reported to CMS, 2019-2025
17 companies · $183 in 2025
The $183 reported for 2025 was more than what a typical Psychiatry provider received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $791 · 2020: $1,042 · 2021: $595 · 2022: $922 · 2023: $617 · 2024: $87.86 · 2025: $183.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $888.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $887.76 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sunovion Pharmaceuticals INC. | $1,058.34 | 2019-2022 | |
| Otsuka America Pharmaceutical, INC. | $579.65 | 2019-2024 | Rexulti |
| Lundbeck LLC | $393.23 | 2019-2025 | Rexulti |
| Janssen Pharmaceuticals, INC | $355.71 | 2019-2025 | Spravato |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $330.60 | 2021-2024 | Caplyta |
| Neurocrine Biosciences, INC. | $312.37 | 2022-2025 | Ingrezza |
| Teva Pharmaceuticals USA, INC. | $257.91 | 2022-2023 | Austedo Xr, Austedo |
| Axsome Therapeutics, INC. | $182.75 | 2022-2024 | Auvelity |
| Takeda Pharmaceuticals U.S.A., INC. | $180.69 | 2019-2023 | Trintellix |
| Abbvie INC. | $150.69 | 2021-2023 | Vraylar |
| Allergan, INC. | $144.96 | 2019-2020 | |
| Eisai INC. | $106.67 | 2020-2021 | |
| Avanir Pharmaceuticals, INC. | $59.85 | 2019 | |
| Shire North American Group INC | $49.28 | 2019 | |
| Alkermes, INC. | $39.52 | 2022-2023 | Aristada, Lybalvi |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vanda Pharmaceuticals INC. | $19.94 | 2022 | |
| Jazz Pharmaceuticals INC. | $15.40 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Bruce Stevens listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.